Closely-held Clarigent is developing a tool to support the early detection of mental health issues, with a goal of preventing suicide in at-risk children and adolescents. “The suicide rate, especially among school-aged...
Using its nanomedicine platform and the capabilities of its cGMP manufacturing facility, NanoViricides (NYSE American: NNVC) is developing therapeutics for a variety of viral infections, including herpes simplex viruses...
As chairman and CEO of Kleo Pharmaceuticals, a private immuno-oncology company developing next-generation bispecific compounds designed to enhance the activity of biologics, Dr. Doug Manion has a distinguished pedigree...
Since COVID-19 was first identified in China late last year, researchers have been working tirelessly to develop diagnostics, therapeutics and vaccines in an effort to prevent the spread of the SARS-CoV-2 virus. Many...
Using the natural pollination process of commercially-reared bees and biological products and controls, Bee Vectoring Technology International (TSXV, CVE:BEE; OTCQB:BEVVF) has developed a pest and disease solution for...
Obalon Therapeutics (NASDAQ:OBLN) is pivoting its business model to a retail strategy of company-managed clinics to deliver its Obalon Balloon System, a weight loss solution that is the first and only swallowable, gas...
Closely-held Diabeloop of Grenoble, France has developed an external Type 1 diabetes management system, known as DBLG1, that connects three components: a continuous glucose monitor, a patch-like insulin pump and an...
Anixa Biosciences (NASDAQ:ANIX) is taking multiple approaches to fighting cancer, developing both a diagnostic and therapeutics, such as a cancer immunotherapy and vaccine, to overcome immuno-suppression. Anixa...
Ocugen (NASDAQ:OCGN) is taking a multi-pronged approach to ophthalmology with a diversified pipeline that includes a breakthrough modifier gene therapy platform, novel biologics and small molecules, targeting a broad...
Using its unique ATLAS proprietary technology platform, Genocea Biosciences (NASDAQ:GNCA) is developing cancer immunotherapies that direct the body’s own tumor-fighting T-cells to the most therapeutically relevant...